2 İ.Ü. İstanbul Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı, İstanbul
3 İ.Ü. İstanbul Tıp Fakültesi Radyasyon Onkolojisi Bilim Dalı, İstanbul
4 İ.Ü. İstanbul Tıp Fakültesi Patoloji Anabilim Dalı, İstanbul
5 İ.Ü. İstanbul Tıp Fakültesi Radyoloji ve Onkoloji Enstitüsü ve Klinik Onkoloji Anabilim Dalı, İstanbul OBJECTIVES
There is still no consensus on the eligibility criteria for breast conservation after neoadjuvant chemotherapy in patients with breast cancer. The present study investigated the long term outcome in patients with breast conservation following chemotherapy to determine its feasibility.
METHODS
Between January 1991 to July 2005, 29 patients with clinical
stage 2 or 3 who underwent breast conservative surgery following
chemotherapy, were included into the study.
RESULTS
The clinical stages before neoadjuvant chemotherapy were as
follows: T0 (n=1), T1 (n=1), T2 (n=14), T3 (n=7), and T4 ( n= 6);
and N0 (n=2), N1 (n=9), and N2 (n=17), and N3 (n=1). Out of
4 ipsilateral breast tumor recurrences, 2 local recurrences (7%)
were detected in the first 5 years, whereas 4 local recurrences
(14%) were detected in the first 10 years. The 5-year and 10-
year local recurrence free rates were 91.5% and 75%, and the
5-year and 10-year overall survival rates were 92% and 78%,
respectively. The 10-year local recurrence-free survival rate
was only found to be higher in patients with T0-2 tumors compared
to patients with T3-4 tumors (86%, vs 60%, p=0.078).
CONCLUSION
Breast conservation after neoadjuvant chemotherapy seems to be
safe in selected patients with locally advanced disease including
those with clinical T0-2 tumors before neoadjuvant chemotherapy.